Aripiprazole in patients with bipolar mania and beyond: an update of practical guidance

References

• Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry 2007;64:543-52
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Vieta E. Efficacy and safety of aripiprazole in the treatment of bipolar disorder: a systematic review. Ann Gen Psychiatry 2009;8:16
   PubMedGoogle Scholar
• Goodwin GM. Evidence-based guidelines for treating bipolar disorder: revised second edition – recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2009;23:346-88
   PubMed Web of Science ®Google Scholar
• Grunze H, Vieta E, Goodwin GM, et al. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2009 on the treatment of acute mania. World J Biol Psychiatry 2009;10:85-116
   PubMed Web of Science ®Google Scholar
• Yatham LN, Kennedy SH, Schaffer A, et al. Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) collaborative update of CANMAT guidelines for the management of patients with bipolar disorder: update 2009. Bipolar Disord 2009;11:225-55
   PubMed Web of Science ®Google Scholar
• De Hert M, Dekker JM, Wood D, et al. Cardiovascular disease and diabetes in people with severe mental illness position statement from the European Psychiatric Association (EPA), supported by the European Association for the Study of Diabetes (EASD) and the European Society of Cardiology (ESC). Eur Psychiatry 2009;24:412-24
   PubMed Web of Science ®Google Scholar
• Young AH, Oren DA, Lowy A, et al. Aripiprazole monotherapy in acute mania: 12-week randomised placebo- and haloperidol-controlled study. Br J Psychiatry 2009;194:40-8
   PubMed Web of Science ®Google Scholar
• Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol 2006;20:536-46
   PubMed Web of Science ®Google Scholar
• Keck PE, Orsulak PJ, Cutler AJ, et al. Aripiprazole monotherapy in the treatment of acute bipolar I mania: a randomized, double-blind, placebo- and lithium-controlled study. J Affect Disord 2009;112:36-49
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese J, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese JR, McIntyre RS, et al. Aripiprazole monotherapy for maintenance therapy in bipolar I disorder: a 100-week, double-blind study versus placebo. J Clin Psychiatry 2007;68:1480-91
   PubMed Web of Science ®Google Scholar
• Fountoulakis KN, Gonda X, Vieta E, et al. Treatment of psychotic symptoms in bipolar disorder with aripiprazole monotherapy: a meta-analysis. Ann Gen Psychiatry 2009;8:27
   PubMedGoogle Scholar
• Burris KD, Molski TF, Xu C, et al. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J Pharmacol Exp Ther 2002;302:381-9
   PubMed Web of Science ®Google Scholar
• Jordan S, Koprivica V, Chen R, et al. The antipsychotic aripiprazole is a potent, partial agonist at the human 5-HT(1A) receptor. Eur J Pharmacol 2002;441:137-40
   PubMed Web of Science ®Google Scholar
• Shapiro DA, Renock S, Arrington E, et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. Neuropsychopharmacol 2003;28:1400-11
   PubMed Web of Science ®Google Scholar
• Poyurovsky M, Weizman R, Weizman A. Aripiprazole's receptor pharmacology and extrapyramidal side effects. Am J Psychiatry 2008;165:398; author reply 98-9
   PubMed Web of Science ®Google Scholar
• Koener B, Hermans E, Maloteaux JM, et al. Paradoxical motor syndrome following a switch from atypical neuroleptics to aripiprazole. Am J Psychiatry 2007;164:1437-8
   PubMed Web of Science ®Google Scholar
• Miller D. Atypical antipsychotics: sleep, sedation, and efficacy. Prim Care Companion J Clin Psychiatry 2004;6(Suppl 2):3-7
   PubMedGoogle Scholar
• Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;18:251-67
   PubMed Web of Science ®Google Scholar
• Bristol-Myers-Squibb, Ltd. OPE. Abilify (aripiprazole) Summary of Product Characteristics. September 2011
   Google Scholar
• McIntyre RS, Soczynska JK, Woldeyohannes HO, et al. Aripiprazole: pharmacology and evidence in bipolar disorder. Expert Opin Pharmacother 2007;8:1001-9
   PubMed Web of Science ®Google Scholar
• Kroeze WK, Hufeisen SJ, Popadak BA, et al. H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs. Neuropsychopharmacology 2003;28:519-26
   PubMed Web of Science ®Google Scholar
• Vieta E, Nolen WA, Grunze H, et al. A European perspective on the Canadian guidelines for bipolar disorder. Bipolar Disord 2005;7(Suppl 3):73-6
   PubMedGoogle Scholar
• Yildiz A, Sachs GS, Turgay A. Pharmacological management of agitation in emergency settings. Emerg Med J 2003;20:339-46
   PubMed Web of Science ®Google Scholar
• McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania-a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol 2005;15:573-85
   PubMed Web of Science ®Google Scholar
• Meehan K, Zhang F, David S, et al. A double-blind, randomized comparison of the efficacy and safety of intramuscular injections of olanzapine, lorazepam, or placebo in treating acutely agitated patients diagnosed with bipolar mania. J Clin Psychopharmacol 2001;21:389-97
   PubMed Web of Science ®Google Scholar
• Kane JM, Sharif ZA. Atypical antipsychotics: sedation versus efficacy. J Clin Psychiatry 2008;69(Suppl 1):18-31
   PubMed Web of Science ®Google Scholar
• Allen MH, Currier GW, Carpenter D, et al. Introduction: methods, commentary, summary. J Psychiatr Pract 2005;11(S1):5-25
   PubMedGoogle Scholar
• Canas F. Management of agitation in the acute psychotic patient – efficacy without excessive sedation. Eur Neuropsychopharmacol 2007;17(Suppl 2):S108-14
   PubMedGoogle Scholar
• Angermeyer MC, Matschinger H. [Neuroleptics and quality of life. A patient survey]. Psychiatr Prax 2000;27:64-8
   PubMed Web of Science ®Google Scholar
• Fagiolini A. Practical guidance for prescribing with aripiprazole in bipolar disorder. Curr Med Res Opin 2008;24:2691-702
   PubMed Web of Science ®Google Scholar
• Vieta E, Owen R, Baudelet C, et al. Assessment of safety, tolerability and effectiveness of adjunctive aripiprazole to lithium/valproate in bipolar mania: a 46-week, open-label extension following a 6-week double-blind study. Curr Med Res Opin 2010;26:1485-96
   PubMed Web of Science ®Google Scholar
• Vieta E, T'joen C, McQuade RD, et al. Adjunctive aripiprazole in bipolar mania partially non-responsive to valproate/lithium: a placebo-controlled study (CN138-134). Am J Psych 2008;165:1316-25
   PubMed Web of Science ®Google Scholar
• Day RK. Psychomotor agitation: poorly defined and badly measured. J Affect Disord 1999;55:89-98
   PubMed Web of Science ®Google Scholar
• APA. Practice guidelines for the treatment of patients with schizophrenia, second edition. Am J Psychiatry 2004;161:1-56
   Web of Science ®Google Scholar
• Hirose S. The causes of underdiagnosing akathisia. Schizophr Bull 2003;29:547-58
   PubMed Web of Science ®Google Scholar
• Miller CH, Fleischhacker WW. Managing antipsychotic-induced acute and chronic akathisia. Drug Saf 2000;22:73-81
   PubMed Web of Science ®Google Scholar
• Rathbone J, Soares-Weiser K. Anticholinergics for neuroleptic-induced acute akathisia. Cochrane Database Syst Rev 2006(4):CD003727
   Google Scholar
• Kane JM, Barnes TRE, Correll CU, et al. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials. J Psychopharmacol 2010;24:1019-29
   PubMed Web of Science ®Google Scholar
• Aitchison KJ, Bienroth M, Cookson J, et al. A UK consensus on the administration of aripiprazole for the treatment of mania. J Psychopharmacol 2009;23:231-40
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Frank E, Scott JA, et al. Metabolic syndrome in bipolar disorder: findings from the Bipolar Disorder Center for Pennsylvanians. Bipolar Disord 2005;7:424-30
   PubMed Web of Science ®Google Scholar
• Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004;27:596-601
   Google Scholar
• Kemp D, Calabrese J, Tran Q, et al. Metabolic syndrome in patients enrolled in a clinical trial of aripiprazole in the maintenance treatment of bipolar I disorder. J Clin Psychiatry; 2010;71:1138-44
   Google Scholar
• Taylor D, Paton C, Kapur S. The South London and Maudsley NHS Foundation Trust and Oxleas NHS Foundation Trust Prescribing Guidelines, 10th edn, 2009
   Google Scholar
• Zimbroff DL, Marcus RN, Manos G, et al. Management of acute agitation in patients with bipolar disorder: efficacy and safety of intramuscular aripiprazole. J Clin Psychopharmacol 2007;27:171-6
   PubMed Web of Science ®Google Scholar
• Bristol-Myers Squibb. Abilify prescribing information. 2011. Available at: http://packageinserts.bms.com/pi/pi_abilify.pdf [Last accessed September 2011]
   Google Scholar
• European Medicines Agency E. Abilify – European Public Assessment Report (EPAR). 2009. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000471/WC500020171.pdf [Last accessed 2011]
   Google Scholar
• Keck PE, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-8
   PubMed Web of Science ®Google Scholar
• El Mallakh RS, Vieta E, Rollin L, et al. A comparison of two fixed doses of aripiprazole with placebo in acutely relapsed, hospitalized patients with bipolar disorder I (manic or mixed) in subpopulations (CN138-007). European neuropsychopharmacology: J Eur College Neuropsychopharmacol 2010;20:776-83
   PubMed Web of Science ®Google Scholar
• Marcus R, Khan A, Rollin L, et al. Efficacy of aripiprazole adjunctive to lithium or valproate in the long-term treatment of patients with bipolar I disorder with an inadequate response to lithium or valproate monotherapy: a multicenter, double-blind, randomized study. Bipolar Disord 2011;13:133-44
   PubMed Web of Science ®Google Scholar
• Carlson B, Ketter T, Sun W et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): a randomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2011;In Press
   Google Scholar
• Colom F, Vieta E, Sanchez-Moreno J, et al. Group psychoeducation for stabilised bipolar disorders: 5-year outcome of a randomised clinical trial. Br J Psychiatry 2009;194:260-5
   PubMed Web of Science ®Google Scholar
• Reinares M, Colom F, Sanchez-Moreno J, et al. Impact of caregiver group psychoeducation on the course and outcome of bipolar patients in remission: a randomized controlled trial. Bipolar Disord 2008;10:511-19
   PubMed Web of Science ®Google Scholar
• Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry 2005;187:235-42
   PubMed Web of Science ®Google Scholar
• Keck PE, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry 2006;67:626-37
   PubMed Web of Science ®Google Scholar
• Thase ME, Jonas A, Khan A, et al. Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized, placebo-controlled studies. J Clin Psychopharmacol 2008;28:13-20
   PubMed Web of Science ®Google Scholar